Molecules Submission Guide

Molecules publishes across organic chemistry, medicinal chemistry, natural products, analytical chemistry, chemical biology, and related areas. The journal is broad, but that does not mean it is indifferent to fit. Editors are still asking whether the paper:

• advances a clear chemistry question
• presents enough evidence to support the claim
• belongs in a broad chemistry venue
• is complete enough to justify external review

That broad-scope position creates a specific editorial filter. Papers need to be understandable and defensible to editors and reviewers who may not live inside a very narrow subfield. If the manuscript depends on specialist assumptions or incomplete validation, the weakness becomes more obvious in a journal like this.

Source: MDPI, Molecules instructions for authors

Before you worry about formatting, decide whether the paper is shaped correctly for this journal. A research article in chemistry requires complete characterization data, explicit assay conditions, and a novelty claim that survives comparison with the nearest prior art.

Ask these questions before you submit:

• is the novelty claim specific, or is it mostly "new compound, new method, new activity" language?
• would another chemist quickly understand why the result matters?
• is the evidence package complete enough to survive skeptical review?
• does the paper fit a broad chemistry readership, not only one tiny technical niche?

If the answer is unclear, the fit problem matters more than the file upload problem.

Molecules editors are usually making a few early judgments very quickly.

The title should state the real advance, not just the subject matter. The abstract should make the novelty and evidence package visible quickly. If a reader finishes the abstract and still cannot tell what is better or different, the package is weak.

This is where many Molecules submissions fail in practice. Make sure:

• structural assignments are complete
• assay conditions are explicit
• controls are adequate
• reproducibility details are present
• claims do not run ahead of the evidence

If reviewers are likely to ask for the missing experiment immediately, the paper often feels premature.

Use the figures to simplify the editorial read:

• scheme or workflow for the chemistry
• one table that makes the comparative result obvious
• one figure that shows why the claim matters

A paper that forces the reader to hunt across dense prose and supplementary material feels weaker than the same work presented cleanly.

The cover letter should do three things:

• state the main advance plainly
• explain why the paper belongs in Molecules specifically
• clarify the audience fit without overselling

It should not rely on vague prestige language or inflated novelty claims.

Most weak Molecules submissions fall into a few patterns:

• novelty is stated too broadly and collapses under comparison with the literature
• characterization is incomplete
• biological claims outrun the actual assay package
• the work is technically valid but too incremental for the framing used
• the paper belongs in a narrower specialty journal

One common mistake is treating "broad journal" like "easy journal." Broad journals often require clearer framing because the work must survive a faster first read.

Before you submit, ask one blunt question:

• if an editor saw only the title, abstract, one main table, and the first figure, would the paper already look both novel enough and complete enough to review?

If the answer is no, fix the package before upload.

Run one extra test before you submit: remove every vague adjective from the abstract and cover letter, then read them again. If the case for the paper becomes blurry once words like "promising" or "important" disappear, the manuscript still needs a sharper comparison, a clearer result statement, or a stronger data package. Molecules can be broad, but the editorial case still has to be concrete.

Before upload, the package should already communicate these five things without requiring author explanation:

• a single clear novelty sentence that names what specifically improved: not "a new compound with antibacterial activity" but "compound X achieves MIC values 8-fold lower than the leading clinically used analogue under identical assay conditions"
• a fair literature comparison visible in a table or figure, showing the claimed advance against the nearest published benchmark under equivalent conditions
• full characterization for all new compounds and methods: complete NMR assignments, HRMS, purity documentation, assay controls, and reproducibility details that allow an expert reader to evaluate the work independently
• a cover letter that makes the Molecules case in plain language: what the advance is, why it fits a broad chemistry readership, and what makes the package complete for review
• a manuscript that already reads as finished: no gaps a reviewer would immediately request, no adjectives standing in for data, no supplementary material doing the job of the main text

In our pre-submission review work with manuscripts targeting Molecules, five patterns generate the most consistent desk rejections worth knowing before submission.

• Novelty claim too broad or incremental for the framing used (roughly 35%). The Molecules instructions for authors position the journal as publishing research advancing knowledge in the relevant chemical fields, requiring that submissions demonstrate a clear and specific novelty contribution rather than extending existing compound classes or biological activities with only minor modification. In our experience, roughly 35% of desk rejections involve manuscripts where the novelty claim is stated in terms of general scope ("new compound," "new application," "new activity") rather than a specific, demonstrable advance beyond the nearest prior art. Editors specifically screen for manuscripts where the novelty is precise enough to survive comparison with the literature, not vague enough to sound larger than it is.

• Characterization package incomplete for new compounds or methods (roughly 25%). In our experience, we find that roughly 25% of submissions introduce new compounds, materials, or analytical methods without complete characterization consistent with the claims being made: missing NMR spectra, inadequate HRMS data, insufficient purity documentation, or bioactivity assays without appropriate positive and negative controls. In practice, Molecules editors assess whether the characterization package fully supports the claims before sending manuscripts to review, and packages where characterization gaps are visible on first read are consistently identified as requiring revision before external review can proceed.

• Biological claims outrun the actual assay evidence in the package (roughly 20%). In our experience, roughly 20% of submissions present bioactivity data that is interpreted in the abstract and conclusion as demonstrating therapeutic potential, mechanism of action, or significant biological consequence, while the actual assay package supports only preliminary in vitro screening results without the orthogonal validation or mechanistic evidence the discussion implies. Molecules editors are specifically sensitive to manuscripts where the biological framing consistently exceeds what the reported experiments can support, and such papers are consistently identified as overstating the findings.

• Work suited to a narrower venue submitted without audience framing (roughly 15%). In our experience, roughly 15% of submissions present chemically strong and technically complete work that would be clearly appropriate for a focused specialty journal, but frame the paper as though a broad multidisciplinary chemistry audience will find it immediately accessible and relevant. Molecules is a broad journal, which means papers need to explain their significance to readers who are not specialists in the exact subfield. Manuscripts that assume specialist knowledge or omit the broader-relevance argument are consistently identified as better suited to a more focused chemistry venue.

• Cover letter restates the abstract instead of explaining the fit (roughly 10%). In our experience, roughly 10% of submissions arrive with cover letters that summarize the study design and primary finding without explaining what makes the paper novel compared to the nearest existing chemistry or bioactivity reports, or why the broad Molecules audience rather than a specialist readership is the right home. Editors use the cover letter to assess whether the manuscript has a clear and defensible novelty position, and letters that restate the abstract without making a fit argument consistently correlate with manuscripts that are also too vague about novelty in the main text.

SciRev community data and Clarivate JCR 2024 bibliometric data provide additional benchmarks when evaluating submission timing.

Before submitting to Molecules, a Molecules submission readiness check identifies whether your novelty position, characterization package, and audience fit meet the editorial bar before you commit to the submission.

1. Molecules journal profile, Manusights.

If you are still deciding whether Molecules is the right fit, compare this guide with the Molecules journal profile. If you want a direct readiness call before you submit, Molecules submission readiness check is the best next step.